Palbociclib: all 236 studies that test it

Page 1 of 3. Open to participants first (41), then studies with results posted, then the rest; newest registration first within each.

• A Study Evaluating the Safety of Inavolisib and Fulvestrant With or Without Palbociclib in Participants With Advanced Breast Cancer (ABC) and Type 2 DiabetesRecruitingNCT07748208Phase 2
• T-DXd Based Therapy Followed by Endocrine Therapy Plus Dual HER2 Blockade in First-line HER2+/ HR+ Metastatic Breast Cancer and Retreatment With T-DXdRecruitingNCT07683754Phase 3
• Neoadjuvant Camrelizumab With Palbociclib for Resectable Esophageal Squamous Cell CarcinomaNot yet recruitingNCT07191977Phase 2
• A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell CarcinomaRecruitingNCT07123090Phase 2
• Comparing Endocrine Therapy Combined With High-Dose Palbociclib and Hydroxychloroquine to Endocrine Therapy Combined With Standard-Dose Palbociclib for Hormone Receptor-Positive and HER2-Negative Advanced Breast CancerNot yet recruitingNCT07061717Phase 3
• A Study of Almonertinib Combined With Palbociclib in Patients With Advanced Solid Tumors Harboring KRAS MutationsRecruitingNCT06947811Phase 1/2
• A Study of Sirolimus (Albumin-Bound) in Combination With Palbociclib and Fulvestrant for the Treatment of Advanced Breast CancerNot yet recruitingNCT06941142Phase 1
• Interventional Study to Evaluate the Combination of Palbociclib + Sunitinib as a Treatment for Advanced Solid TumorsRecruitingNCT06940349Phase 1/2
• Study of Pazopanib Combined With Palbociclib for Refractory Solid Tumors With Co-amplified in the 11q13(FGF3/4/19/CCND1)RecruitingNCT06895733Phase 1/2
• A Study of Sirolimus (Albumin-Bound) in Combination With Palbociclib and Fulvestrant for the Treatment of Advanced Breast CancerRecruitingNCT06856200Not applicable
• A Study of Mirdametinib in Combination With Palbociclib in People With LiposarcomaRecruitingNCT06843967Phase 1/2
• The Efficacy and Safety of CDK4/6 Inhibitors in Combination with Endocrine Therapy in the Neoadjuvant TreatmentNot yet recruitingNCT06810492Not applicable
• Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)RecruitingNCT06757634Phase 3
• Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGSNot yet recruitingNCT06692491Phase 2
• Backline Treatment of Advanced Hepatocellular Carcinoma With PalbociclibRecruitingNCT06478927Not applicable
• Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast CancerRecruitingNCT06380751Phase 3
• The CDK4/6 Inhibitor Dosing Knowledge (CDK) StudyRecruitingNCT06377852Phase 3
• Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)RecruitingNCT06126276Phase 2
• Palbociclib and Pembrolizumab in SarcomaRecruitingNCT06113809Phase 1
• Exploring Cancer-Associated Thromboembolism Prognosis Biomarkers and PolymorphismsRecruitingNCT06065592Phase 1
• Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast CancerRecruitingNCT06062498Phase 2
• OPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older AdultsNot yet recruitingNCT05949424Phase 4
• Palbociclib Combined With Afatinib for Advanced Squamous Carcinoma of Esophagus or Gastroesophageal JunctionRecruitingNCT05865132Phase 2
• A Randomized Study Comparing the Immune Modulation Effect of Ribociclib, Palbociclib, and Abemaciclib in ER+/HER2- EBCRecruitingNCT05766410Phase 2
• Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal CancerRecruitingNCT05725200Phase 2
• Tazemetostat and Palbociclib With CPX-351for R/R AMLRecruitingNCT05627232Phase 1
• Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening TrialRecruitingNCT05564377Phase 2
• Pilot Trial for Treatment of Recurrent GlioblastomaRecruitingNCT05432518Early Phase 1
• Cyclin dEpendent Kinase in tRiple nEGatIVe brEast canceR - a "Window of Opportunity" StudyNot yet recruitingNCT05067530Phase 2
• A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast CancerRecruitingNCT04985266Phase 2
• Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma Who Experienced Disease Progression on a PD-1/L1 InhibitorRecruitingNCT04966481Phase 3
• Neoadjuvant Treatment With Palbociclib and Exemestane Plus Trastuzumab and Pyrotinib in Estrogen Receptor (ER)-Positive, HER2-positive Breast CancerNot yet recruitingNCT04858516Phase 2
• A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast CancerRecruitingNCT04802759Phase 1/2
• Encorafenib, Binimetinib and Palbociclib in BRAF-mutant Metastatic Melanoma CELEBRATERecruitingNCT04720768Phase 1/2
• Umbrella Biomarker-Guided Therapy in NPCNot yet recruitingNCT04605562Phase 2
• PLATFORM Study of Precision Medicine for Rare TumorsRecruitingNCT04423185Phase 2
• Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid TumorsRecruitingNCT03454035Phase 1
• A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast CancerRecruitingNCT03424005Phase 1/2
• Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)RecruitingNCT03297606Phase 2
• Trial of Palbociclib in Second Line of Advanced Sarcomas With CDK4 Overexpression.RecruitingNCT03242382Phase 2
• The Drug Rediscovery Protocol (DRUP Trial)RecruitingNCT02925234Phase 2
• Testing Palbociclib (PD-0332991) as Potentially Targeting Treatment in Cancers With CDK4 or CDK6 Amplification (MATCH - Subprotocol Z1C)Active, not recruitingNCT06390839Phase 2Results posted
• Testing Palbociclib (PD-0332991) as a Potential Targeted Treatment in Cancers With CCND1, 2, 3 Amplification (MATCH-Subprotocol Z1B)Active, not recruitingNCT04439201Phase 2Results posted
• Phase 2a Study of ZW25 in Combination With Palbociclib Plus FulvestrantCompletedNCT04224272Phase 2Results posted
• Palbociclib + Ganitumab In Ewing SarcomaTerminatedNCT04129151Phase 2Results posted
• A Phase 1/2 Trial of ARV-471 Alone and in Combination With Palbociclib (IBRANCE®) in Participants With ER+/HER2- Locally Advanced or Metastatic Breast CancerCompletedNCT04072952Phase 1/2Results posted
• Binimetinib and Palbociclib or TAS-102 in Treating Patients With KRAS and NRAS Mutant Metastatic or Unresectable Colorectal CancerCompletedNCT03981614Phase 2Results posted
• Palbociclib in Combination With Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL)CompletedNCT03792256Phase 1Results posted
• Hydroxychloroquine, Palbociclib, and Letrozole Before Surgery in Treating Patients With Estrogen Receptor Positive, HER2 Negative Breast CancerCompletedNCT03774472Phase 1/2Results posted
• Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid TumorsCompletedNCT03709680Phase 2Results posted
• Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone MetastasisCompletedNCT03691493Phase 2Results posted
• To Reduce the Use of Chemotherapy in Postmenopausal Patients With ER-positive and HER2-positive Breast Cancer (TOUCH)CompletedNCT03644186Phase 2Results posted
• Testing the Effects of Palbociclib and Fulvestrant or Letrozole for Patients 70 Years of Age of Older With Metastatic Breast CancerCompletedNCT03633331Phase 2Results posted
• A Study of ZN-c5 in Subjects With Breast CancerCompletedNCT03560531Phase 1/2Results posted
• Preoperative Palbociclib in Patients With DCIS of the Breast That Are Candidates for SurgeryTerminatedNCT03535506Phase 2Results posted
• T-DM1 and Palbociclib for Metastatic HER2 Breast CancerCompletedNCT03530696Phase 2Results posted
• Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)CompletedNCT03526250Phase 2Results posted
• Palbociclib and Cetuximab in Metastatic Colorectal CancerCompletedNCT03446157Phase 2Results posted
• Survival Prolongation by Rationale Innovative GenomicsTerminatedNCT03386929Phase 1/2Results posted
• PF-06804103 Dose Escalation in HER2 Positive and Negative (Negative Only in Part 2) Solid TumorsTerminatedNCT03284723Phase 1Results posted
• Fulvestrant, Palbociclib and Erdafitinib in ER+/HER2-/FGFR-amplified Metastatic Breast CancerCompletedNCT03238196Phase 1Results posted
• Phase II Trial Evaluating the Efficacy of Palbociclib in Combination With Carboplatin for the Treatment of Unresectable Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaCompletedNCT03194373Phase 2Results posted
• Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)Active, not recruitingNCT03155620Phase 2Results posted
• Palbociclib After CDK and Endocrine Therapy (PACE)Active, not recruitingNCT03147287Phase 2Results posted
• Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast CancerCompletedNCT03007979Phase 2Results posted
• Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast CancerActive, not recruitingNCT02947685Phase 3Results posted
• Neoadjuvant Study of Palbociclib in Combination With Letrozole and Trastuzumab in Stage II-III ER+ HER2+ Breast CancerTerminatedNCT02907918Phase 2Results posted
• Palbociclib With Everolimus + Exemestane In BCCompletedNCT02871791Phase 1/2Results posted
• Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung CancerCompletedNCT02785939Phase 2/3Results posted
• Pembrolizumab, Endocrine Therapy, and Palbociclib in Treating Postmenopausal Patients With Newly Diagnosed Metastatic Stage IV Estrogen Receptor Positive Breast CancerActive, not recruitingNCT02778685Phase 2Results posted
• Palbociclib in Treating Patients With Metastatic HER-2 Positive Breast Cancer With Brain MetastasisTerminatedNCT02774681Phase 2Results posted
• Palbociclib and Endocrine Therapy for LObular Breast Cancer Preoperative Study (PELOPS)Active, not recruitingNCT02764541Phase 2Results posted
• Palbociclib / Letrozole or Fulvestrant in African American Women With HR+ HER2- Breast CancerCompletedNCT02692755Phase 2/3Results posted
• Palbociclib In Combination With Letrozole As Treatment Of Post-Menopausal Women With HR+, HER2- Advanced Breast CancerCompletedNCT02679755Phase 4Results posted
• Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast CancerCompletedNCT02668666Phase 2Results posted
• Two Different Schedules of Palbociclib + Second Line Endocrine Therapy in Estrogen Receptor Positive, HER2 Neg Advanced/Metastatic Breast CancerCompletedNCT02630693Phase 2Results posted
• Palbociclib Plus Letrozole For Postmenopausal Women With HR(+) HER2(-) Advanced Breast Cancer For Whom Letrozole Is Deemed AppropriateCompletedNCT02600923Phase 3Results posted
• Palbociclib in Molecularly Characterized ER-positive/HER2-negative Metastatic Breast CancerCompletedNCT02536742Phase 2Results posted
• Safety and Efficacy of PD0332991 (Palbociclib), a Cyclin-dependent Kinase 4 and 6 Inhibitor, in Patients With Oligodendroglioma or Recurrent Oligoastrocytoma Anaplastic With the Activity of the Protein RB PreservedCompletedNCT02530320Phase 2Results posted
• PALbociclib CoLlaborative Adjuvant StudyActive, not recruitingNCT02513394Phase 3Results posted
• Dose-Escalation Study Of Palbociclib + Nab-Paclitaxel In mPDACCompletedNCT02501902Phase 1Results posted
• Palbociclib Pharmacokinetics Study In Postmenopausal Chinese Women With ER (+), HER2 (-) Advanced Breast CancerCompletedNCT02499146Phase 1Results posted
• Safety And Efficacy Study Of Palbociclib Plus Cetuximab Versus Cetuximab To Treat Head And Neck CancerCompletedNCT02499120Phase 2Results posted
• A Study of Palbociclib in Combination With Bazedoxifene in Hormone Receptor Positive Breast CancerCompletedNCT02448771Phase 1/2Results posted
• A Study of Palbociclib in Combination With Fulvestrant or Tamoxifen as Treatment for Metastatic Breast CancerCompletedNCT02384239Phase 2Results posted
• A Study To Describe The Effect Of Impaired Hepatic Function Of The Pharmacokinetics Of PalbociclibCompletedNCT02334800Phase 1Results posted
• Phase II Trial of Palbociclib in Patients With Metastatic Urothelial Cancer After Failure of First-Line ChemotherapyTerminatedNCT02334527Phase 2Results posted
• A Study Of Palbociclib (PD-0332991) + Letrozole VS. Placebo+ Letrozole For 1st Line Treatment Of Asian Postmenopausal Women With ER+/HER2- Advanced Breast Cancer [PALOMA-4]CompletedNCT02297438Phase 3Results posted
• A Phase II Randomized Study Evaluating the Biological and Clinical Effects of the Combination of Palbociclib With Letrozole as Neoadjuvant Therapy in Post-Menopausal Women With Estrogen-Receptor Positive Primary Breast CancerCompletedNCT02296801Phase 2Results posted
• PD 0332991 and Cetuximab in Patients With Incurable SCCHNCompletedNCT02101034Phase 1/2Results posted
• A Phase II Study of Androgen Deprivation Therapy With or Without Palbociclib in RB-Positive Metastatic Prostate CancerCompletedNCT02059213Phase 2Results posted
• Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast CancerCompletedNCT02040857Phase 2Results posted
• Phase III Palbociclib With Endocrine Therapy vs. Capecitabine in HR+/HER2- MBC With Resistance to Aromatase InhibitorsCompletedNCT02028507Phase 3Results posted
• Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3)CompletedNCT01942135Phase 3Results posted
• Efficacy and Safety of PD-0332991 in Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and SunitinibCompletedNCT01907607Phase 2Results posted
• A Study of Palbociclib in Addition to Standard Endocrine Treatment in Hormone Receptor Positive Her2 Normal Patients With Residual Disease After Neoadjuvant Chemotherapy and SurgeryCompletedNCT01864746Phase 3Results posted
• A Study of GDC-0810 Single Agent or in Combination With Palbociclib and/or a Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast CancerTerminatedNCT01823835Phase 1/2Results posted
• A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2)CompletedNCT01740427Phase 3Results posted
• PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast CancerActive, not recruitingNCT01723774Phase 2Results posted
• A Phase 1 Trial of TST of PD 0332991 Followed by Cytarabine and Mitoxantrone for Adults With Relapsed and Refractory Acute Leukemias and High-Risk MyelodysplasiaTerminatedNCT01701375Phase 1Results posted

← Palbociclib overview